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Abstract
Background: Bogijetong decoction (BGJTD) is a herbal drug formulation used in the traditional Asian medicine to
treat neuropathic insults associated with diabetes and anticancer therapy. To understand the biological basis of
BGJTD on protective effects against neuropathy, we investigated physiological and biochemical responses of the
sciatic nerves deranged by taxol injection or crush injury in the rats.
Methods: Dissociated Schwann cells and neurons were prepared from the sciatic nerve and dorsal root ganglia
(DRG) respectively and were treated with taxol and BGJTD. The sciatic nerve in the rat was injected with taxol or
given crush injury. Animals were then administered orally with BGJTD. Effects of BGJTD treatment on cultured cells
and in vivo sciatic nerves and DRG tissues were examined by immunofluorescence staining and western blot
analysis. Sciatic nerve regeneration was assessed by histological observation using retrograde tracing technique and
by behavioral hot plate test. Eighteen different herbal components of BGJTD were divided into 4 subgroups and
were used to select herbal drugs that enhanced neurite outgrowth in cultured neurons.
Results: Morphological abnormalities in the sciatic nerve axons and DRG tissue caused by taxol injection were
largely improved by BGJTD treatment. BGJTD treatment enhanced neurite outgrowth in cultured DRG neurons and
improved Schwann cell survival. Phospho-Erk1/2 levels were elevated by BGJTD administration in the injured- or
taxol-injected sciatic nerves. Vimentin phosphorylation catalyzed by cell division cycle 2 (Cdc2) kinase was induced
from Schwann cells in the sciatic nerves after taxol injection and crush injury, and phospho-vimentin levels
were further upregulated by BGJTD treatment. Retrograde tracing of DiI-labeled DRG sensory neurons revealed
growth-promoting activity of BGJTD on axonal regeneration. A drug group (Be) composed of 4 active herbal
components which were selected by neurite growth-enhancing activity was as effective as BGJDT for the
recovery of thermal sensitivity of the hind paws which had been suppressed by taxol administration.
Conclusions: These data suggest that BGJTD and its active herbal components may protects the peripheral
nerve from damage caused by taxol injection and nerve crush.
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Background
Peripheral neuropathy, referring to histological and
physiological abnormalities caused by infections, nerve
damages, diabetes, anticancer therapy and others [1],
generates deficits of sensory and motor functions and
affects the quality of life significantly. At cellular levels,
structural alterations in peripheral axons and Schwann
cells may be related with deficits in myelination and
axonal transport that lead to abnormal conduction prop-
erty of action potential through the axon [2].
Taxol, known to stabilize microtubule assembly, pre-
vents dynamic regulation of spindle components during
mitosis and thus has been used as anticancer therapeutic
agent [3]. Yet, clinical studies reported that repeated ad-
ministration of taxol can generate peripheral neuropathy
by disrupting microtubule structure in axons [4–6].
Addition of taxol to cultured neurons resulted in de-
creased neurite outgrowth, and in vivo administration of
taxol in rats generated morphological changes of myelin-
ated fibers and degeneration of Schwann cells [7, 8].
Other studies indicated morphometric alterations via ab-
normal action potential propagation [9]. Interestingly
however, in vivo application of taxol at low dose was
shown to improve axonal regeneration after spinal cord
injury, by stabilizing microtubule structure and reducing
glial scarring around the injury cavity [10].
Bogijetong decoction (or Bogijetong-tang; BGJTD) is
the herbal prescription that was developed to reduce
neuropathy caused by diabetes and anticancer therapy
[11, 12]. In our previous studies, BGJTD treatment into
the streptozotocin (STZ)-induced diabetes animal model
induced Schwann cell responses in terms of increased
phosphorylation of vimentin by cell division cycle 2
(Cdc2) and induction of phospho-Erk1/2 and β1 integrin
proteins [13]. Also in an animal model given both sciatic
nerve injury and taxol treatments, in vivo administration
of BGJDT improved the regenerative responses of in-
jured axons in addition to Schwann cell activation as oc-
curred similarly in STZ-injected animals [14]. While
these studies suggest that BGJTD may play a role in
regulating peripheral neuropathy, overall neuropathic re-
sponsiveness to STZ-injected animals is indirect, and the
neuropathy caused by combined physical and chemical
paradigm may complicate the interpretation of neural
responses to BGJTD. Here, to understand the mechanis-
tic basis on how BGJTD is beneficiary for alleviating
neuropathy, we investigated the effects of BGJTD treat-
ment on the sciatic nerve which had been either injected
taxol or given crush injury. By examining morphological
and biochemical responses of peripheral neurons and
Schwann cells, we found that BGJTD has a protective
function of peripheral neural tissues against neuropathic
insults. Noting that BGJTD is composed of as many as
18 different herbal components, we performed additional
experiment to select active components that could repre-
sent the efficacy of BGJTD. A small decoction group (Be)
composed of 4 herbal components showed a similar




Dried BGJTD was obtained from Daejeon University
Korean Hospital (Daejeon, Korea) where the quality con-
trol of herbal drugs was in accordance with the Standard
of Korean Pharmacopoeia (ver. 9, Korea Food and Drug
Administration, Korea). The procedure of identification
of 18 individual drugs was executed by Dr. Chung-Sik
Cho at Daejeon University Oriental Hospital (Daejeon,
Korea). The voucher specimens were deposited in the
Herbarium of Pharmacognosy, Department of Oriental
Medicine, Daejeon University (Daejeon, Korea). The key
information in herbal drugs is summarized in Table 1.
BGJTD was used clinically at Korean Traditional Medi-
cine Hospital of Daejeon University (Daejeon, Korea)
and its efficacy was verified [11, 12]. A mixture of dried
BGJT was suspended in distilled water for 2 h, boiled for
3 h, and filtered with Whatman filter paper (Grade 1,
Whatman Inc, Clifton, NJ, USA) three times. The extract
was frozen at −70 °C for 4 h and freeze-dried for 24 h.
The yield for BGJTD extract was 24 g for 178 g of the ini-
tial raw materials. Purified material was stored at −20 °C
and used for experiment after diluting with physiological
saline solution (1 mg of extract residue/ml in 0.9 % NaCl
solution). For the experiment screening the active
components, individual herbal drugs of BGJTD were
divided into 4 decoction groups according to the
traditional medicinal theory (Table 2). Herbal extracts
were prepared similarly as above.
HPLC analysis
Herbal extracts of BGJTD and of Ba, Bb, Bc, Bd, and
Be subgroups were purified by filtration through
0.45 μm PVDF membrane, and standard solutions
such as amygdalin, chlorogenic acid, ginsenosides Rg1
and Rb1, nodakenin, albiflorin, paeoniflorin, puerarin,
and 5-HMF were diluted with ultra–purified water to
a range of 50 – 500 ppm. The herbal extracts and
standard solutions were analyzed by LC20A Series
HPLC system (Shimadzu, Kyoto, Japan). The analysis
system includes an Agilent eclipse plus C18 (250x4.6 mm)
with linear elution with acetonitrile gradient at a flow rate
of 1.0 ml/min. Sample aliquots (10 μl) were injected
to the column, which was set to 40 °C. UV values for
detection were 215 nm for amygdalin, 203 nm for Rg1
and Rb1, 230 nm for puerarin, albiflorin and paeniflorin,
280 nm for 5-HMF and chlorogenic acid, and 330 nm
for nodakenin.
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Experimental animals
Sprague-Dawley rats (male, 200–250 g, Samtago, Seoul,
Korea) or Balb/c mice (male, 22–25 g, Samtago, Seoul,
Korea) were maintained in an animal room with regu-
lated temperature (22 °C), 60 % of humidity, and 12-h
light/dark cycle (light on 7 am to 7 pm). They were
allowed to eat commercial pellet chow (Samyang Co.,
Seoul, Korea) and drink water ad libitum. All procedures
were in strict accordance with the NIH guide for the
care and use of laboratory animals and approved by the
Committee on Use of Live Animals for Teaching and
Research at Daejeon University (Daejeon, Korea).
Animal surgery
For an experiment examining the effects of BGJTD in
taxol-treated sciatic nerve, animals were randomly
assigned into dimethysulfoxide (DMSO) vehicle-injected
group (Veh), taxol-injected group (Taxol), and taxol plus
BGJTD treated group (Taxol + BGJTD). Sciatic nerves
and DRG at levels of lumbar 4 and 5 were prepared
from individual animals and used for immunofluores-
cence staining and western blot analysis. Rats were anes-
thetized by injecting intraperitoneally a single dose of a
mixture of ketamine (80 mg/kg) and xylazine (5 mg/kg).
Taxol (3.6 mg/ml of 5 % DMSO; 1.25 mg/kg of body
weight) and equivalent volume of DMSO as vehicle con-
trol were slowly injected by using a Hamilton syringe
(10 μl-model, Innovative Labor System GmbH, Germany)
Table 1 Sources of BGJTD
Scientific name Part Production area Specimen number Amount (g)
Astragalus membranaceus Root Jeongseon, ROKa KNP0011 30
Panax ginseng C. A. Meyer Root Geumsan, ROK KNP0038 4
Angelica gigas Root Jeongseon, ROK KNP0008 7.5
Rehmannia glutinosa Rhizome Geumsan, ROK KNP0087 10
Cnidium officinale Makino Rhizome Younghae, ROK KNP0028 5
Paeonia lactiflora Pall Root Younghae, ROK KNP0085 7.5
Salvia miltiorrhiza Root, rhizome Sichuan, China KNP0095 12
Prunus persica Seed Hebei, China KNP0087 7.5
Carthamus tinctorius Flower Xingang, Taiwan KNP0020 7.5
Spatholobus suberectus Dunn Stem Jeongseon, ROK KNP0102 12
Epimedium Koreanum NAKAI Whole Cheorwon, ROK KNP0030 10
Lumbricidae Whole Jiangxi, China KNP0053 5
Pueraria thunbergiana Root Younghae, ROK KNP0089 8
Pteridium aquilinum var. latiusculum Rhizome Guangdong, China KNP0023 8
Albizia julibrissin Durazz Peel Gyeongju, ROK KNP0007 12
Uncaria rhynchophylla Branch Hunan, China KNP0120 12
Chaenomeles sinensis Fruit Yeongcheon, ROK KNP0022 8
Crassostrea gigas Shell Mokpo, ROK KNP0074 12
Total amount 178
aRepublic of Korea
Table 2 Subgroups of BGJTD
Subgroups Compositiona Applications
Ba Astragalus membranaceus (30),
Panax ginseng C. A.Meyer
(4, ginsenoside Rg1, Rb1)b,
Epimedium Koreanum NAKAI (10),
Cibotium barometz J. Smith (8)
Replenishing qi and
yin energy
Bb Angelica gigas (7.5, chlorogenic
acid, nodakenin), Rehmannia
glutinosa (7.5, 5-HMF), Cnidium
officinale Makino (7.5),
Spatholobus suberectus Dunn (12)
Increasing erythropoietic
activity and blood function








Bd Uncaria rhynchophylla (12),
Pueraria lobate Ohwi
(8, puerarin), Crassostrea gigas
(12), Albizia julibrissin Durazz (12),
Chaenomeles sinensis Koebhne (8)
Relieving pain and
regulating yang energy
Be Panax ginseng C. A.Meyer
(4, ginsenoside Rg1, Rb1),
Angelica gigas (7.5), Paeonia
lactiflora Pall (7.5, albiflorin,
paeoniflorin), Crassostrea gigas (8)
aNumber in parenthesis: grams in preparing each decoction
bUnderlined in parenthesis are chemical ingredients which were identified by
HPLC analysis
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into the sciatic nerve pre-exposed on the middle thigh. A
similar procedure of local injection of taxol into the per-
ipheral nerves were used in previous studies to examine
regenerative or degenerative effects of taxol on the nerve
[15, 16]. In order to induce acute effect on the micro-
tubule integrity within axon of the peripheral nerve, we
injected taxol with higher dosage than those used to inves-
tigate the regenerative responses of peripheral and spinal
cord axons after injury [10, 16]. Twenty four hours later,
BGJTD (400 mg/kg) was administered orally and was sup-
plemented on a daily basis for 4 more days. Animals were
sacrificed at day 7.
In an experiment investigating the effects of BGJTD on
regenerative responses of injured axons, animals were ran-
domly assigned into three groups: sciatic nerve injury plus
BGJTD treatment (SNI + BGJTD), sciatic nerve injury plus
saline (SNI + Sal), and non-treatment (Intact). To induce
nerve injury, the sciatic nerve was exposed from the mid-
dle thigh and crush injury was given by holding the nerve
with the forceps for 30 s twice as described previously
[17]. BGJTD or saline was administered orally 24 h later
and supplemented on a daily basis for 4 more days.
Animals were sacrificed at day 7, and sciatic nerve or
DRG sections (20 μm thickness) were prepared.
Retrograde tracing of DRG neurons
For retrograde tracing of the sensory neurons in the
DRG, the sciatic nerve from anesthetized rats with keta-
mine and xylazine was exposed and, immediately after
nerve injury, fluorescent lipophilic carbocyanine dye
l,l'-dioctodecyl-3,3,3',3'tetramethylindocarbocyanine
perchlorate (DiI; 5 μl of 0.5 % in DMSO) was applied
with a micropipette to the area 10 mm distal to the
injury site. After suturing the incision, animals were
recovered from the narcosis and returned to their cages.
BGJTD or saline was administered orally 24 h later and
supplemented on a daily basis for 4 more days, and the
animals were sacrificed at day 7. The total number of DiI-
labeled neurons from three nonconsecutive sections
(20 μm thick) per animal was counted, and the mean per-
centage of labeled cells was compared between BGJTD
and saline administered groups.
Primary Schwann cell and DRG sensory neuron culture
For Schwann cell culture, intact sciatic nerve (1 cm
length) was dissected from the rats and dissociated with
0.5 mg/ml type XI collagenase (Sigma, USA) in BME for
90 min at 37 °C. DRG neurons at lumbar 4–5 in adult
rats were prepared 3 days after sciatic nerve injury, dis-
sected, and dissociated similarly for neuron culture.
After washing twice with BME, cells were treated with
5 μg/ml type SII trypsin for 15 min and followed by
inhibition reaction for 5 min in 50 μg/ml of soybean
trypsin inhibitor, 0.5 mM EDTA, and 20 μg/ml of DNase
I. Cells (1 × 104 cells per 24-well plate) were plated onto
12 mm coverslips (Bellco, Glass Inc. Vineland, USA)
precoated with 0.01 % poly-L-ornithine (Sigma, St.
Louis, MO) and laminin (0.02 mg/ml, Collaborative
Research, Bedford, MA). Cells were cultured for 12 h,
changed to BME containing 10 % serum (5 % fetal
bovine serum plus 5 % horse serum) and 2 mM glutam-
ine and 1 % penicillin-streptomycin. Cells were treated
with herbal drugs (0.5 mg/ml) and incubated for 48 h
before the harvest for immunofluorescence staining.
For DRG sensory neuron and Schwann cell co-culture,
Schwann cells (1 × 104 cells per 12 mm coverslip in
24-well plate) were cultured for 24 h and DRG sensory
neurons (1.5 × 102 cells) were added. The coculture was
maintained in 500 μl of BME medium supplemented
with 10 % serum and treated with taxol (0.01 mg/ml)
alone or together with BGJTD (0.5 mg/ml) for 48 h prior
to cell harvest. Equivalent volume of DMSO and saline
as vehicle controls for taxol and BGJTD was treated,
respectively. After immunofluorescence staining with
antibodies against neurofilament-200 (NF-200) (1:400,
Sigma), βIII-tubulin (TUJ1, 1:400, Covance), S100β
(H-56, 1:400, Santa Cruz Biotech.), and caspase 3 (1:500,
Cell Signaling), digital images of neuronal process were
captured and transferred to the Adobe Photoshop Pro-
gram. The length of neurite processes exhibiting clear
outgrowth (longer than cell diameter) from the cell body
was analyzed by i-Solution software program (Image
and Microscope Technology, Burnaby, Canada). Mean
neurite length was determined by analyzing at least
30 sensory neurons which were randomly selected in
each experiment.
Western blot analysis
Nerve segment was suspended in 100–200 μl of triton
lysis buffer (20 mM Tris, pH 7.4, 137 mM NaCl, 25 mM
β-glycerophosphate, pH 7.14, 2 mM sodium pyrophos-
phate, 2 mM EDTA, 1 mM Na3VO4, 1 % Triton X-100,
10 % glycerol, 5 μg/ml leupeptin, 5 μg/ml aprotinin,
3 μM benzamidine, 0.5 mM DTT, 1 mM PMSF) and
was sonicated. The supernatant was taken after centrifu-
gation at 12,000 rpm for 10 min at 4 °C. Protein (15 μg)
was used for SDS-polyacrylamide gel electrophoresis
and immunoblotting with anti-phospho-Erk1/2 anti-
body (1:4000, Cell Signaling), anti-Cdc2 antibody,
anti-phospho-vimentin antibody (1:2,000, MBL) that
binds specifically to phosphorylated vimentin (serine
55) by Cdc2 kinase [18], and horseradish peroxidase
(HRP)-conjugated secondary antibodies (1:1000; goat
anti-rabbit; Santa Cruz, or sheep anti-mouse; Amersham
Biosciences, Buckinghamshire, UK). Densitometric
analysis of protein bands in the X-ray film was deter-
mined using the i-Solution software (Image & Micro-
scope Technology).
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Immunofluorescence staining
Samples were fixed with 4 % paraformaldehyde and 4 %
sucrose in PBS at room temperature for 40 min, permea-
blized with 0.5 % nonidet P-40 in PBS, and blocked with
2.5 % horse serum and 2.5 % bovine serum albumin for
16 h at room temperature. Staining procedure was
performed by incubating with primary antibodies raised
against Cdc2 (1:100, Santa Cruz Biotech.), vimentin
(1:1,000, Chemicon, Temecula, USA), phospho-vimentin
(1:400, MBL), NF-200 (1:400, Sigma), βIII-tubulin (TUJ1,
1:400, Cavance), S100β (1:400, Santa Cruz Biotech.),
phospho-Erk1/2 (1:400, Cell Signaling), and GAP-43
(1:400, Santa Cruz Biotech.) followed by fluorescein-goat
antimouse (1:400, Molecular probes, Eugene, OR, USA)
or rhodamine-goat anti-rabbit secondary antibodies
(1:400, Invitrogen, Carlsbad, CA, USA) in 2.5 % horse
serum and 2.5 % bovine serum albumin for 90 min at
room temperature. Cellular nuclei were stained with
2.5 μg/ml of Hoechst dye 33258 (bis-benzimide; Sigma)
for 10 min before the final washing with 0.1 % Triton
X-100 in PBS, and the sections or cells were cover-slipped
with gelatin mount medium. Samples were viewed with a
Nikon fluorescence microscope, and the images were
captured by Nikon camera. The merged images were pro-
duced using layer-blending mode options of the Adobe
Photoshop. For quantitative analysis of image data, aver-
age signals from 4 nonconsecutive sections per each
animal were compared among experimental groups.
Hot plate test
Sciatic nerves of Balb/c mice (male, 22–24 g) were ex-
posed on the middle thigh and taxol (1.25 mg/kg) or
equivalent volume of DMSO vehicle was focally injected
into the sciatic nerve. Twenty four hours later, herbal
decoction (400 mg/kg) or saline was administered orally
and was supplemented on a daily basis for 4 more days.
On day 7 after taxol injection, animals were subjected to
thermal sensitivity test on a hot plate. Animals were
adapted for 10 min on the surface on a hot plate
adjusted to 30 °C, and immediately after, were placed for
30 s on the plate adjusted to 50 °C. The latency to the
lifting response of the hind paw and the number of with-
drawal frequency were determined by analyzing real-
time images of animal movement which were captured
by a digital camera.
Statistical analysis
Data were presented as mean ± standard error of
mean (SEM). The mean number data in individual
groups were compared by the Student’s t-test or one-
way ANOVA followed by Tukey test post-hoc analysis
(SPSS computer software version 21.0), and statisti-
cally significant differences were reported as *P < 0.05,
**P < 0.01, ***P < 0.001.
Results
To validate the chemical profile of herbal extracts,
BGJTD and 5 subgroups, we carried out HPLC analysis
for chemical ingredients of herbal drugs. BGJTD and 5
subgroup extracts showed the peak profiles in the
chromatogram that coincide with those of standard
chemical solutions (Fig. 1). Specifically, HPLC profiles of
BGJTD identified puerarin in Pueraria lobate Ohwi, albi-
florin in Paeonia lactiflora pall, paeoniflorin in Paeonia
lactiflora pall, 5-HMF in Rehmannia glutinosa, and
chlorogenic acid in Angelica gigas. Other ingradients in
Ba to Be subgroup decoctions are indicated in Table 2.
To investigate whether taxol and BGJTD influence on
structural integrity of the peripheral nerve, sciatic nerve
axons were visualized by immunofluorescence staining
using anti-NF-200 antibody as axon marker. Comparison
among experimental groups showed that the mean
length of individual axons in the longitudinal nerve
sections were significantly decreased by taxol injection
indicating their fragmentation and then improved by
BGJTD administration (Fig. 2a, b). Given that taxol
stabilizes mictotubule assembly, we further investigated
axonal morphology by immunostaining with neuron-
specific β-III tubulin antibody (TUJ-1). Staining pattern
of the sciatic nerve axons, as seen by elongated fibers in
DMSO vehicle control, was disintegrated by taxol injec-
tion, which was then largely recovered in its integrity by
BGJTD administration (Fig. 2c). Examination of neurons
in the DRG at lumbar level 5, where the cell bodies of
sciatic nerve sensory axons reside, showed structural dis-
ruption of the neurons by taxol injection into the nerve.
However, in animals administered with BGJTD, some, but
not all, of neurons showed the morphology that is similar
to those in the control animals (arrows in Fig. 2d).
Next, we examined the effects of taxol and BGJTD
treatments on the neurite outgrowth of cultured DRG
neurons. Taxol injection significantly reduced neurite
length, but cotreatment with BGJTD improved neurite
extension similar to vehicle-treated control group
(Fig. 3a). Examination of DRG neurons merged with
Hoechst-stained nuclear images revealed that many of
non-neuronal cell nuclei in the culture were highly colo-
calized with the neurite processes, which was observed
most clearly in a group treated with taxol and BGJTD
(arrows in Fig. 3b).
Given that taxol interferes dynamic regulation of
microtubule assembly, Schwann cells in the nerve might
be affected adversely by taxol. Some Schwann cells in
the control group showed thin, elongated morphology
having physical contact with other cells. After taxol
treatment, cells became more spherical and smaller
(Fig. 4a), but co-treatment with BGJTD reverted them
into an elongated morphology, which was similarly ob-
served in control Schwann cells. To determine the
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Fig. 1 HPLC profile of BGJTD and its subgroup extracts. Peaks that coincide with standard chemical solutions are marked by vertical arrows, and
UV values applied to detect peaks are indicated in the figure
Fig. 2 Morphological changes of sciatic nerve axons and DRG neurons after taxol injection and BGJTD treatments. Sciatic nerve was exposed and
treated with DMSO vehicle, taxol, or taxol plus BGJTD, and longitudinal sections of the nerve at the injected location (a, c) and DRG at lumbar
level 5 (d) were used for immunofluorescence staining for NF-200 and βIII-tubulin. The number of axons whose length is longer than 100 μm, as
illustrated with dotted rectangles in (a), was counted from the images, averaged from 3 nonconsecutive sections and compared among 3 experimental
groups. Quantitative data are shown in (b). Soma DRG neurons was marked by arrows in (d). *p < 0.05, ***p < 0.001 (One-way ANOVA,
number of animals = 4). Scale bars in (a, c, d): 100 μm
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involvement of taxol and BGJTD in cell death regula-
tion, levels of caspase 3 as a marker of apoptotic cell
death were analyzed in cultured Schwann cells. Caspase
3 signals were clearly induced by taxol, but decreased to
a large extent by BGJTD treatment (Fig. 4b, c).
To investigate that BGJTD and taxol treatments alter
neural cell activity, we examined Erk1/2 activation in the
sciatic nerve and DRG. Phospho-Erk1/2 levels was not
altered by taxol alone, but increased by BGJTD adminis-
tration (Fig. 5a). In the DRG, phospho-Erk1/2 levels
were decreased by taxol, and then increased by BGJTD
administration (Fig. 5b). As another indicator of nerve
activation, we examined induction of Cdc2 kinase and
its phosphorylation of vimentin intermediate filament
protein as a substrate, which is known to be induced
strongly but transiently from Schwann cells in the injured
peripheral nerve [19, 20]. Cdc2 was induced in the sciatic
nerve by taxol injection, and BGJTD treatment upregulated
Cdc2 with concomitant induction in phospho-vimentin
(Fig. 5c). Immunohistochemical analysis for the sciatic
nerve showed that both Cdc2 and phospho-vimentin were
detected together in S100β-labeled Schwann cells (Fig. 5d).
We further investigated whether BGJTD was beneficiary
to axonal regeneration of the sciatic nerve after crush
injury. Phospho-Erk1/2 levels were increased by crush in-
jury and further upregulated by BGJTD treatment (Fig. 6a).
Cdc2 was clearly induced in both proximal and distal por-
tions of the sciatic nerves at day 7 after injury (Fig. 6b).
Then the treatment of BGJTD suppressed Cdc2 production
almost exclusively in the proximal stump while further
increasing in the distal stump. Phospho-vimentin was
weakly detected in the injured sciatic nerves but greatly
increased in the distal portion of the nerve after BGJTD
treatment. Immunofluorescence staining of the nerve fibers
revealed that axonal elongation to the distal portion of the
nerve was restricted to a certain extent when measured
3 days after injury; however, axon extension was much
improved by BGJTD treatment (Fig. 6c). For quantitative
analysis of axon regeneration by BGJTD, DRG neurons
were retrogradely labeled by fluorescence dye DiI. DiI-
labeled neurons, as an indicator of regenerating sensory
axons, were clearly observed in many of DRG neurons, and
the total number of labeled neurons was significantly higher
in BGJTD-treated group than control group (Fig. 6d).
Fig. 3 Effects of BGJTD on the neurite outgrowth of DRG neurons. a Quantitative comparison of neurite outgrowth. b Representative images of
DRG neurons co-cultured with Schwann cells. The neurites were visualized by immunostaining with anti-βIII tubulin antibody (green), and the
distribution of co-cultured Schwann cells were identified by Hoechst nuclear staining (blue). In (a), neurite length was determined by analyzing
more than 20 neurons in 7–10 random microscopic fields, averaged 4 independent experiments, and compared among experimental groups.
Error bars denote standard error of mean (SEM). ***p < 0.001 (One-way ANOVA, number of independent experiments = 4). Scale bar: 50 μm
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BGJTD is a decoction composed of as many as 18 dif-
ferent herbal drugs. As an initial step to sort out the
active components in its efficacy on the nerve repair, we
divided them into 4 different groups (i.e., Ba, Bb, Bc, and
Bd) based on the description of the traditional medicine
(Table 2). After treating individual herbal drugs to
cultured DRG neurons, we selected the most effective
herbal drug from each group in inducing neurite out-
growth, and prepared the fifth herbal drug group,
termed ‘Be’ (Table 2) (manuscript in preparation). We
then treated each decoction to taxol-treated DRG
neurons, and compared the neurite outgrowth. In vivo
taxol injection suppressed neurite outgrowth and abro-
gated Schwann cell survival to a large extent as indicated
by Hoechst nuclear staining (Fig. 7a, b). While the
recovering effects of drug treatment on neurite out-
growth were variable, Be decoction was the most effect-
ive to enhance neurite outgrowth. It was also noted that
the number of Hoechst-stained nuclei in Be was higher
than other drugs and the elongated neurite was in close
contact with many nuclei particularly at the tip (marked
with a dotted circle in the enlarged image in Fig. 7b). In
Be group, GAP-43 protein signals were not only
observed in the cell body as other groups, but also were
seen clearly in the elongating neurites. We further inves-
tigated the behavioral effect of BGJTD and Be extract on
heat sensitivity. Withdrawal frequency and latency time
in lifting the hind legs from the hot surface were signifi-
cantly impaired by taxol administration, but were
improved by BGJTD or Be treatment (Fig. 8a, b).
Discussion
The objective of the present study was to investigate
whether BGJTD was effective for protecting the periph-
eral nerves from damage caused by taxol injection and
physical injury. Taxol generated structural disruption of
the nerve, and hampered Schwann cell survival
adversely. Morphological and biochemical analyses of
the sciatic nerve and DRG tissue revealed that taxol and
crush injury generated nerve damage in a similar way.
Importantly, these pathological injuries were largely
recovered by BGJTD treatment. By sorting out the
herbal components of BGJTD in terms of their activity
to enhance neurite outgrowth, we selected the active
herbal components, and a decoction Be from selected
drugs was as effective as BGJTD in facilitating neurite
outgrowth and responding to heat stimulation.
Since the initial discovery and pharmacological
characterization, taxol has been used as a chemothera-
peutic drug. However, together with several other anti-
cancer drugs such as platinum compounds, taxanes,
vinka alkaloids, bortezomib, and thalidomide, a large
portion of patients given taxol therapy showed neur-
opathy accompanying severe pain [21, 22]. Considering
stabilization effect of taxol on microtubule assembly,
axonal cytoskeletal structures mainly composed of
microtubule assembly might be damaged by taxol ther-
apy. Studies with animals and in vitro culture showed
that taxol caused inhibition of neurite outgrowth of
cultured neurons, disrupted myelin structure, and re-
tarded conduction of action potential [7–9].
Fig. 4 Regulation of Schwann cell survival by BGJTD treatment. Schwann cells prepared from intact sciatic nerve were treated with DMSO vehicle,
taxol, and taxol plus BGJTD. Fixed cells were used for immunostaining with anti-S100β antibody (a) and anti-caspase 3 antibody (b). Cells were also
stained with Hoechst33258 to visualize individual nuclei (blue). a Morphological comparison of S100β-stained Schwann cells after different treatments.
b Immunofluorescence staining of caspase 3 in cultured Schwann cells. c Quantitative comparison of caspase 3-positive cells in cultured cells after
different treatments. A percentage of caspase 3-positive cells from randomly selected microscopic fields (more than 5 fields) were determined from
each experiment. *p < 0.05, ***p < 0.001 (One-way ANOVA, number of independent experiments = 4). Scale bars in (a-c): 100 μm
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After peripheral nerve injury, neuropathy can occur
during repair process [2, 23]. BGJTD has been used for
the treatment of neuropathic pain and regulation of
blood glucose levels in diabetic patients in the clinical
traditional medicine, implicating the possible ameliorat-
ing effects of BGJTD on diabetic or anticancer-related
neuropathy [11, 12]. To understand biological basis of
BGJTD action, we performed experiment using two
models of peripheral nerve injury, and reached following
conclusions; first, we found that taxol injection not only
inhibited neurite outgrowth of cultured DRG neurons
but also induced morphological abnormalities resulting
in apoptotic death of primary Schwann cells. Taxol may
have a detrimental effect on axonal regrowth by inhibit-
ing Schwann cell interaction with axons [24]. Further-
more, functional degeneration of Schwann cells by taxol
injection may prevent axon myelination and lead to
morphometric alterations in action potential propaga-
tion [25, 26]. Secondly, direct effects of taxol on the
sciatic nerve axons were most clearly seen by immuno-
histochemical analysis in which βIII tubulin-labeled
axons were largely degenerated by taxol injection. The
structure of βIII tubulin-labeled DRG neurons at lumbar
5 was severely disintegrated by taxol injection, and
phospho-Erk1/2 signals in DRG neurons were largely
decreased by taxol. Previous studies have shown that
phospho-Erk1/2 is induced in the peripheral nerve after
injury, and can be transported retrogradely into the cell
body where it leads to expression of target protein in-
volved in axonal repair [27–29]. Here, taxol that may
cause structural derangement from axon to soma could
disrupt retrograde transport of Erk1/2 signaling, as has
been shown by retarded transport of tracer in taxol-
treated nerve [30]. Finally, BGJTD administration pro-
duced regenerative responses in the peripheral nerve.
Signal intensity of apoptotic marker protein caspase 3 in
taxol-treated Schwann cells was reduced by BGJTD, and
Cdc2 activity, which was induced in the sciatic nerve
after taxol injection or crush injury, was upregulated in
the distal portion of the nerve. Moreover, neurite exten-
sion in cultured DRG neurons and axonal staining of in
vivo sciatic nerves were improved in the BGJTD-treated
Fig. 5 Effects of taxol and BGJTD treatments on Erk1/2 and Cdc2 activity in the sciatic nerve. Western blot analysis of phospho-Erk1/2 in the sciatic
nerves (a) and in the DRG (b) after taxol injection and BGJTD treatments (T + B). c Western blot analysis of Cdc2 and phospho-vimentin in the sciatic
nerves treated with DMSO vehicle, taxol, and taxol plus BGJTD. d Representative images showing Cdc2 and phospho-vimentin signals in S100β-
labeled Schwann cells. Longitudinal sections from distal portion of the nerve treated with taxol and BGJTD were used in this experiment. Western
blotting images in (a-c) are the representatives from 3 independent experiments. Quantitative comparison of mean band intensity for target proteins
relative to actin control in western blotting are shown in lower panels in (a-c). Scale bars in (d): 100 μm
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groups, compared to corresponding taxol-treated
ones.
We have reported that vimentin phosphorylated by
Cdc2 kinase is induced in Schwann cells from the
injured nerve and involved in regenerative responses
[19, 20]. Here, Cdc2 and phospho-vimentin were
detected from taxol-injected sciatic nerve, and interest-
ingly, their levels were further upregulated by BGJTD
treatment. Given that Cdc2 activation in Schwann cells
is responsible for axonal regeneration, BGJTD-mediated
Cdc2 induction in Schwann cells may facilitate repair
process in the taxol-treated nerves. Indeed, neurite out-
growth in the taxol-treated DRG neurons was recovered
by BGJTD to the level of control ones, and in vivo axon
morphology, as identified by βIII-tubulin staining, was
clearly improved by BGJTD. The protective effect of
BGJTD was also shown in Schwann cells in which cas-
pase 3 signals induced by taxol was largely decreased by
BGJTD treatment. Thus, protective activity of BGJTD in
both individual axons and Schwann cells may improve
nerve repair, as demonstrated by increases in axon
staining in the distal nerve stump and retrograde label-
ing of DRG sensory neurons (Fig. 6).
Our data showing the induction of Cdc2 and
phospho-vimentin levels by BGJTD suggest possible
molecular basis on how BGJTD acts on neuropathy. The
BGJTD treatment upregulated Cdc2 levels and its phos-
phorylation of vimentin in taxol-injected nerves and the
distal stump in the injured nerve. It was previously re-
ported that Schwann cell activation in terms of Cdc2-
vimentin pathway is beneficiary to promote axonal
regeneration of the peripheral nerve [20]. After periph-
eral nerve injury, axons in the distal stump degenerate
and regrow from the proximal end, and in this process,
Schwann cells are actively involved in eliminating degen-
erating debris and guiding the growth cones at the front
[24]. Molecular factors that are expressed from activated
Schwann cells including growth factors and anti-
inflammatory cytokines may play a role in alleviating
peripheral nerve neuropathies [31, 32]. Timely inter-
action of Schwann cells with axons is important for
recovering distal portion of injured nerve with minimizing
Fig. 6 Effects of BGJTD treatment on the axonal regeneration after nerve injury. a Western blot analysis of phospho-Erk1/2 after sciatic nerve injury
(SNI) and BGJTD treatment. b Western blot analysis of Cdc2 and phospho-vimentin in the sciatic nerve after injury (SNI) and BGJTD treatment. In
(a) and (b), western blotting images are the representatives from 2–3 independent experiments. Quantitation of protein band intensity relative to actin
control are shown in lower panels. c Distribution of axons in the sciatic nerve after crush injury. Axons were visualized in the proximal, injury, and distal
stumps (6 mm each) in the longitudinal sections by immunofluorescence staining for NF-200. (Lower) Number of axons crossing midline (dotted) are
counted from each images, averaged from nonconsecutive sections from each animal, and compared between experimental groups (One-way
ANOVA, **p< 0.01, number of animals = 4). d Retrograde tracing of DiI-labeled sensory neurons in the DRG (left). Quantitative comparison of DiI-labeled
DRG neurons between saline-and BGJTD-treated groups (right).*p < 0.05 (Student’s t-test, number of independent experiments = 4). Scale
bars in (c, d): 100 μm
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inflammation [33]. It was reported that activation of
Cdc2-vimentin pathway in Schwann cells was linked to
activation of membrane intergrin, which is further in-
volved in intercellular communication with regrowing
axons [20, 24]. Whether BGJTD therapy is functionally
associated with Schwann cell communication via integrin
remains to be determined.
BGJTD is a decoction composed of 18 different herbal
drugs and has been used in Asian medicine to treat
neuropathy caused by diabetes and anticancer therapy
Fig. 7 Effects of BGJT subgroup decoctions on neurite outgrowth of taxol-treated DRG sensory neurons. Six days after taxol or DMSO
vehicle injection in vivo into the sciatic nerve, DRG neurons were cultured in the presence of individual decoctions Ba to Be (0.5 mg/ml)
for 48 h and harvested for immunostaining. a Comparison of neurite length among experimental groups. b Representative images of cultured cells
after immunofluorescence staining with NF-200 (Green) and GAP-43 (red). Cell nuclei were visualized by nuclear staining with Hoechst 33258 (blue). In
(a), neurite length was determined by analyzing more than 20 neurons in 7–10 random microscopic fields, averaged 4 independent experiments, and
compared among experimental groups. Error bars in (a) denote standard error of mean (SEM). *P < 0.05, **P < 0.01, ***p < 0.001 (One-way ANOVA,
N = 4). Scale bars in (b): 100 μm
Fig. 8 Effects of taxol, BGJTD, and Be drugs on the heat sensitivity. Mice were given taxol followed by oral administration of BGJTD or Be, and
were subjected to measure the lifting frequency of the hind paws (a) and the latency period after placing on the hot plate (b). Error bars in (a) denote
standard error of mean (SEM). *P < 0.05, **P < 0.01, ***p < 0.001 (One-way ANOVA, number of animals =4)
Ahn et al. BMC Complementary and Alternative Medicine  (2016) 16:402 Page 11 of 13
[11]. A decoction shengmai san, which is used for the
treatment of cardiovascular disorders in traditional
medicine, shares the herbal component Ginseng radix
with BGJTD and was reported to be involved in promot-
ing regenerative responses after spinal cord injury [34].
Ginsenoside components such as Rg1 and Re were
reported to facilitate axonal regeneration after peripheral
nerve injury, or neuronal survival [35, 36], and ginseno-
side Re was shown to activate Schwann cells in the
injured nerve thereby promoting axonal regeneration
[37]. However, given that BGJTD contains diverse herbal
components, it is difficult to determine whether the effi-
cacy of BGJTD is related to combinatorial activity or
due to some specific components. Here, as an initial step
to screen the possible active herbal components, we
categorized 18 individual drugs into 4 groups based on
description of the traditional medicine, and selected the
most active components inducing neurite outgrowth of
cultured neurons; a similar procedure was applied previ-
ously to search herbal drugs for therapeutic application
to neurodegenerative diseases [38]. Our data showed
that Be decoction composed of 4 active herbal drugs is
as effective as BGJTD in inducing heat sensitivity of the
hind paws. Further studies are critical to determine
whether Be extract is comparable to BGJTD in regulat-
ing regenerative responses in association with peripheral
nerve neuropathy.
Conclusions
In conclusion, our data showed that BGJTD, which is
used clinically in the traditional Asian medicine, has a
protective effect on neuropathic insults such as taxol
injection or crush injury. By using in vitro screening pro-
cedure, we have selected some active herbal components,
of which decoction displayed the efficacy of reinducing the
optimal levels of heat sensitivity in taxol-treated animals.
Accordingly, our data provide the biological basis of BGJDT
on the treatment of the peripheral nerve neuropathy, and
further implicate that some of the traditional medicinal
descriptions on the efficacy of the herbal drugs may be ap-
plicable to the scientific approaches to identifying the active
ingredients for the purpose of the therapeutic strategy.
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